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2The purpose of this study is to evaluate the clinical usefulness of modulated arc (mARC) 
treatment techniques. The mARC treatment plans of the non-small cell lung cancer (NSCLC) 
patients were performed in order to verify the clinical usefulness of mARC. A pre study was 
conducted to find the most competent plan condition of mARC treatment and the usefulness 
of mARC treatment plan was evaluated by comparing it with the other Arc treatment plans 
such as Tomotherapy and RapidArc. In the case of mARC, the optimal condition for the 
mARC plan was determined by comparing the dosimetric performance of the mARC plans 
with the use of various parameters. The various parameters includes the photon energies (6 
MV, 10 MV), optimization point angle (6°-10° intervals), and total segment number (36-59 
segment). The best dosimetric performance of mARC was observed at 10 MV photon energy 
and the point angle 6 degree, and 59 segments. The each treatment plans of three different 
techniques were compared with the following parameters: conformity index (CI), 
homogeneity index (HI), target coverage, dose in the OARs, monitor units (MU), beam on 
time and the normal tissue complication probability (NTCP). As  a result, all three different 
treatment techniques show the similar target coverage. The mARC results the lowest V20 and 
MU per fraction compared with both RapidArc and Tomotherapy plan. The mARC plan 
reduces the beam on time as well. Therefore, the results of this study provided a satisfactory 
result which mARC technique is considered as a useful clinical technique for radiation 
treatment.
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3I. INTRODUCTION
Helical Tomotherapy (Accuray Inc., Madison, WI) is an arc-based, photon intensity 
modulated radiotherapy (IMRT) delivery system that utilizes a rotating helical fan beam with 
a multi-leaf collimator (MLC) containing 64 binary leaf-pairs [1]. RapidArc (Varian Medical 
Systems, Palo Alto, CA) is also an arc-based photon IMRT delivery system, but the entire 
treatment volume can be covered by a single rotation of the gantry unlike helical tomotherapy. 
As an alternative to serial tomotherapy, IMAT utilized multiple coplanar arcs with constant 
gantry speed, constant dose rate, continuous gantry rotation and dynamic MLC, but each arc 
delivered only one level of intensity [2]. RapidArc is capable of varying the MLC leaf 
position, dose rate and gantry rotation speed simultaneously during delivery. These 
techniques achieved significantly better target dose homogeneity while maintaining 
acceptable sparing of organs at risk (OARs) [3].
The mARC (Prowess Panther & Siemens, Concord, CA) technique has recently become 
available for Siemens ARTISTE linear accelerators as an analogue to RapidArc and VMAT 
(Elekta Oncology Systems, Crawley, West Sussex, UK) available for Varian and Elekta 
machines [4-6]. All three techniques offer highly conformal treatment, since those techniques 
have a large number of beam directions, which may create a complete or partial gantry 
rotation. Moreover the beam on time decreases notably due to continuous gantry rotation, 
MLC movement and small segment number [7]. The purpose of this study therefore is to 
evaluate the clinical usefulness of mARC treatment techniques for NSCLC case. A pre study 
was conducted to find the most competent plan condition of mARC treatment and the 
usefulness of mARC treatment plan was evaluated by comparing it with the other Arc 
treatment plans such as Tomotherapy and RapidArc. 
4II. Material and method
Three types of radiation treatment plans, mARC, Tomotherapy and RapidArc plans, were 
performed for 10 NSCLC patients. Chest CT images were obtained with 3 mm slice thickness.
Gross tumor volume (GTV) and planning target volume (PTV) were delineated by one 
qualified radiation oncologist. PTV1 is generated from a constant 1.5 cm cranio-caudal 
margin and a constant 1 cm radial margin of GTV1 (supraclavicular mass). PTV2 is 
generated from a constant 1.5 cm cranio-caudal margin and a constant 1 cm radial margin of 
GTV2 (mediastinum). The prescribed dose to the PTV1 and PTV2 was 6000 cGy in 30 
fractions over 6 weeks. Prowess Panther™  5.2 (Prowess Panther & Siemens, Concord, CA) 
for mARC, HiART™  Tomotherapy Planning Station 4.2.3 (Accuray Inc., Madison, WI) for 
Tomotherapy, and Eclipse™  Treatment Planning System 10.0 (Varian Medical Systems, Palo 
Alto, CA) for RapidArc were used as a treatment planning system. 
2.1 mARC
Conventional arc treatment modalities such as RapidArc and VMAT, those have continuous 
dose delivery function. In other words, they can deliver radiation dose continuously while the 
gantry and MLC are in motion. mARC, by contrast, only implement radiation beam on while 
the MLC remains static, although the gantry moves along an arclet of a few degrees. The 
mARC beam is switched on in a small arclet angle around each optimization point angle [7]. 
Figure 1 shows schematic illustration of mARC. In the case of mARC, the optimal condition 
for the mARC plan was determined by comparing the dosimetric performance of the mARC 
plans with the use of various parameters. The various parameters includes the photon 
energies (6 MV, 10 MV), optimization point angle (6°-10° intervals), and total segment 
number (36-59 segment). The optimized mARC plan is compared with the conventional arc 
therapy techniques such as Helical Tomotherapy and RapidArc.
52.2 Conventional arc therapy
In Tomotherapy plan case, main parameters such as the field width, pitch, and modulation 
factor were fixed, i.e. 1-cm field width, a 0.3 pitch, and a 2 modulation factor. The isocenter 
was placed at the center of summation structure of PTV1 and PTV2. For the RapidArc, Two 
arcs treatment plans with the same isocenter were performed. In the case of tumor located on 
the left side, the first arc rotated counterclockwise from gantry angle 179°–359° and the 
second arc rotated clockwise from 359° to 179°. A mirrored configuration was used when the 
tumor is located on the right side. The total arc angle was 718° degree. The two arc technique 
was expected to achieve better target dose coverage than the single arc because the 
independent optimization of two arcs allows each arc create a completely unrelated sequence 
of MLC shapes, dose rates and gantry speed combinations. It is recommended when the 
target and OARs are closely located so that the treatment planning has some limitations.
2.3 Comparison of the three different techniques
The each treatment plans of three different techniques were compared with the following 
parameters: conformity index (CI), homogeneity index (HI), target coverage, dose in the 
OARs, monitor units (MU), beam on time and the normal tissue complication probability 
(NTCP). The conformity index (CI) was defined as:
௏ು೅ೇ்௏ುೇ
௏೅ೇ்௏ುೇ  (1)
Where VTV is the treatment volume of the prescribed isodose lines and VPTV is the volume of 
the PTV. TVPV is the volume of VPTV within the VTV. It represents that the smaller the CI 
value, the better conformal the PTV fitting [8]. The homogeneity index (HI) was defined as: 
6(஽మ%ି஽వఴ%)஽೘೐೏೔ೌ೙ (2)
Homogeneity Index (HI) is defined as the maximum dose delivered to 2% of the target 
volume (D2%) minus the dose delivered to 98% of the target volume (D98%) divided by the 
median dose (Dmedian) to the target volume. The average cumulative DVH was generated for 
the PTV and OARs from the individual DVHs. Paired two tailed t-test was used to detect any 
statistically significant differences in these parameters among the 3 different techniques [9]. 
The NTCP was used the Lyman NTCP model with parameters described by Burman et al. 
and Lyman [10, 11].
7III. Result and discussion
3.1 Target coverage
The mean volume of the PTV1 and PTV2 was 42.3 ± 3.162 cc and 51.3 ± 11.597 cc. In the 
case of mARC, the best dosimetric performance of mARC was observed with the main 
factors of 10 MV photon energy and the point angle 6 degree, 59 segments. The values of the 
study among the various parameters in mARC were tabulated in Table 1. The dose color 
wash from 24 Gy (40%) to 66 Gy (110%) of the three arc techniques were illustrated in 
Figure 2. Both mARC and tomotherapy plans had a better conformity compared with 
RapidArc, with a relative improvement of 28% and 29% in CI of PTV1, and with a relative 
improvement of 32% and 7% in CI of PTV2. However, RapidArc produced the best dose 
homogeneity, as reflected in the least formula 1, and it was lower than that of mARC and 
tomotherapy plan (Table 2).
3.2 Organs at risks
mARC produced the lowest V20 (volume of lung-PTV receiving > 20 Gy). The V20 for 
mARC was 6%, with an absolute difference of 1.3% lower than tomotherapy and 0.2% lower 
than RapidArc. Mean lung dose was 6.45 Gy, 0.16 Gy lower than tomotherapy. However, 0.2 
Gy higher than RapidArc. The mean esophagus dose was 4.07 Gy, with an absolute 
difference of 4.15 Gy lower than RapidArc, it was similar in mARC and tomotherapy plan. 
The mean airway dose of tomotherapy plan was 14.87 Gy, which was the lowest among the 
three techniques (4.43 Gy lower than mARC and 4.41 Gy lower than RapidArc). The dose 
volume histograms for the PTV and OAR with different techniques were shown in Figures. 3 
and 4. 
3.3 Monitor units (MU) and beam-on time
8The mARC results the lowest V20 and MU per fraction compared with both RapidArc and 
Tomotherapy plan as decreasing 214 MU and 81 MU, respectively. 
The treatment time using mARC technique was 307.4s, and was shorter than tomotherapy
plan by 498s. RapidArc plan gave the shortest treatment time, with a treatment time of 188.5s.
9IV. Conclusion
The target coverages were similar in all three different treatment techniques. Among those, 
the RapidArc produced the best dose homogeneity index. However, the conformity index of 
RapidArc were 1.510 at PTV1 and 1.632 at PTV2, of Tomotherapy were 1.072 at PTV1 and 
1.520 at PTV2, of mARC were 1.100 at PTV1 and 1.116 at PTV2. The mARC produced the 
lowest V20. However, RapidArc produced the best mean lung dose. Both mARC and 
RapidArc plans had a shorter treatment time, compared with tomotherapy, relatively fast of 
62% and 77% in treatment time. Therefore, the results of this study provided a satisfactory 
result which mARC technique is considered as a useful clinical technique for radiation 
treatment.
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Table 1. Summary of the study parameters the mARC treatment technique
Point 
angle
segment
Lung Airway Cord Thyroid Esophagus Heart PTV1 PTV2
V20 Mean Max Mean Mean Mean D90 D90
% Gy %
mARC
6MV
6 59 6.0 20.402 19.668 9.015 4.579 1.398 96.7 95.1
7 51 6.0 21.694 18.061 10.344 6.923 1.287 95.2 95.1
8 45 6.1 21.784 20.694 11.824 6.078 1.315 96.3 94.3
9 40 6.9 24.004 22.645 15.145 8.631 1.348 94.4 94.2
10 36 7.7 24.477 20.681 18.769 8.462 1.389 94.1 93.4
10MV
6 59 6.0 19.503 19.602 8.856 4.071 1.201 97.8 94.6
7 51 6.1 21.600 20.272 9.518 6.043 1.131 95.9 94.8
8 45 6.1 21.254 19.835 10.334 6.455 1.234 96.8 95.4
9 40 7.0 23.727 25.687 13.641 8.042 1.115 95.3 95.3
10 36 6.5 25.090 21.844 16.991 8.253 1.182 95.2 93.9
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Table 2. Summary of the study parameters among the 3 different treatment techniques
mARC RapidArc Tomotherapy P value
Conformity 
index
PTV1:
1.100±0.271 PTV1: 1.510±0.042 PTV1: 1.072±0.061
a:p <0.756
b:p <0.001
PTV2: 
1.116±0.152 PTV2: 1.632±0.047 PTV2: 1.520±0.110
a:p <0.001
b:p <0.001
Homogeneity
index
PTV1: 
0.123±0.021 PTV1: 0.06±0.027 PTV1: 0.228±0.002
a:p <0.001
b:p <0.013
PTV2: 
0.092±0.011 PTV2: 0.098±0.003 PTV2: 0.030±0.008
a:p <0.001
b:p <0.174
Mean lung-PTV dose 
(Gy) 6.45±0.229 6.25±0.177 6.61±0.146
a:p <0.081
b:p <0.038
V20 (lung-PTV) (%) 6.0±0.462 6.2±0.255 7.3±0.970 a:p <0.002b:p <0.383
V10 (lung-PTV) (%) 26.0±0.316 23.3±0.158 24.8±0.101 a:p <0.001b:p <0.001
V5 (lung-PTV) (%) 41.0±0.792 38.6±0.158 39.4±1.029 a:p <0.041b:p <0.001
Mean (esophagus) 
(Gy) 4.07±0.071 8.22±0.151 4.05±0.079
a:p <0.739
b:p <0.001
Mean (Airway) (Gy) 19.3±0.255 19.5±0.412 14.87±0.016 a:p <0.001b:p <0.399
Treatment time (s) 307.4±7.515 188.5±8.214 805.4±40.343 a:p <0.001b:p <0.001
Monitor units 465.9±20.210 680.3±15.951 547.4±30.592 a:p <0.001
b:p <0.001
NTCP (lung-PTV) 
(%)
7.68±0.608 7.45±0.707 7.85±0.453 a:p <0.074
b:p <0.083
Abbreviations: a = mARC vs. Tomotherapy, b = mARC vs. RapidArc
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Figure Captions.
Figure 1. Schematic illustration of mARC
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Figure 2. Dose distribution of the three different treatment techniques in a representative case.
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Figure 3. The dose volume histogram for planning target volume of the three different 
treatment techniques.
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Figure 4. The dose volume histogram for normal organ (lung, esophagus, airway) of the three 
different treatment techniques.
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